These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 1836225)

  • 1. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus.
    Myers RH; Vonsattel JP; Paskevich PA; Kiely DK; Stevens TJ; Cupples LA; Richardson EP; Bird ED
    J Neuropathol Exp Neurol; 1991 Nov; 50(6):729-42. PubMed ID: 1836225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus.
    Ma L; Nicholson LF
    Brain Res; 2004 Aug; 1018(1):10-7. PubMed ID: 15262199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Connexin expression in Huntington's diseased human brain.
    Vis JC; Nicholson LF; Faull RL; Evans WH; Severs NJ; Green CR
    Cell Biol Int; 1998 Nov; 22(11-12):837-47. PubMed ID: 10873295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological differences between the motor onset and psychiatric onset of Huntington's disease, focusing on the nucleus accumbens.
    Hirano M; Iritani S; Fujishiro H; Torii Y; Habuchi C; Sekiguchi H; Yoshida M; Ozaki N
    Neuropathology; 2019 Oct; 39(5):331-341. PubMed ID: 31264738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative neuropathological changes in presymptomatic Huntington's disease.
    Gómez-Tortosa E; MacDonald ME; Friend JC; Taylor SA; Weiler LJ; Cupples LA; Srinidhi J; Gusella JF; Bird ED; Vonsattel JP; Myers RH
    Ann Neurol; 2001 Jan; 49(1):29-34. PubMed ID: 11198293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A histochemical and immunohistochemical analysis of the subependymal layer in the normal and Huntington's disease brain.
    Curtis MA; Waldvogel HJ; Synek B; Faull RL
    J Chem Neuroanat; 2005 Jul; 30(1):55-66. PubMed ID: 16108100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early loss of neostriatal striosome neurons in Huntington's disease.
    Hedreen JC; Folstein SE
    J Neuropathol Exp Neurol; 1995 Jan; 54(1):105-20. PubMed ID: 7815073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropathological classification of Huntington's disease.
    Vonsattel JP; Myers RH; Stevens TJ; Ferrante RJ; Bird ED; Richardson EP
    J Neuropathol Exp Neurol; 1985 Nov; 44(6):559-77. PubMed ID: 2932539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease.
    Harris GJ; Pearlson GD; Peyser CE; Aylward EH; Roberts J; Barta PE; Chase GA; Folstein SE
    Ann Neurol; 1992 Jan; 31(1):69-75. PubMed ID: 1531910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression.
    Novak MJ; Seunarine KK; Gibbard CR; Hobbs NZ; Scahill RI; Clark CA; Tabrizi SJ
    Cortex; 2014 Mar; 52():98-112. PubMed ID: 24405816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphometric analysis of the prefrontal cortex in Huntington's disease.
    Sotrel A; Paskevich PA; Kiely DK; Bird ED; Williams RS; Myers RH
    Neurology; 1991 Jul; 41(7):1117-23. PubMed ID: 1829794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons.
    Rudinskiy N; Kaneko YA; Beesen AA; Gokce O; Régulier E; Déglon N; Luthi-Carter R
    J Neurochem; 2009 Oct; 111(2):460-72. PubMed ID: 19686238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Nitropropionic acid neurotoxicity: visualization by silver staining and implications for use as an animal model of Huntington's disease.
    Miller PJ; Zaborszky L
    Exp Neurol; 1997 Jul; 146(1):212-29. PubMed ID: 9225755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A neuropathological study of a case of lupus erythematosus with chorea.
    Kuroe K; Kurahashi K; Nakano I; Morimatsu Y; Takemori H
    J Neurol Sci; 1994 May; 123(1-2):59-63. PubMed ID: 8064322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in nine enzyme markers for neurons, glia, and endothelial cells in agonal state and Huntington's disease caudate nucleus.
    Butterworth J
    J Neurochem; 1986 Aug; 47(2):583-7. PubMed ID: 2874190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective sparing of a class of striatal neurons in Huntington's disease.
    Ferrante RJ; Kowall NW; Beal MF; Richardson EP; Bird ED; Martin JB
    Science; 1985 Nov; 230(4725):561-3. PubMed ID: 2931802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data.
    D JF; Stout JC; Poudel G; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
    Br J Psychiatry; 2016 Jun; 208(6):571-8. PubMed ID: 26678864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-Sectional Area Analysis of the Head of the Caudate Nucleus in Huntington's Disease.
    Furukawa F; Ishikawa K; Yokota T; Sanjo N
    Eur Neurol; 2019; 81(1-2):13-18. PubMed ID: 31013498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal distribution in the putamen in Huntington's disease.
    Roos RA; Pruyt JF; de Vries J; Bots GT
    J Neurol Neurosurg Psychiatry; 1985 May; 48(5):422-5. PubMed ID: 3158722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.